These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32707032)

  • 41. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy.
    Miyamoto H; Hernandez DJ; Epstein JI
    Hum Pathol; 2009 Dec; 40(12):1693-8. PubMed ID: 19683331
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.
    Seiler D; Randazzo M; Klotz L; Grobholz R; Baumgartner M; Isbarn H; Recker F; Kwiatkowski M
    BJU Int; 2012 Jul; 110(2):195-200. PubMed ID: 22093744
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Level of invasion into fibromuscular band is an independent factor for positive surgical margin and biochemical recurrence in men with organ confined prostate cancer.
    Kim A; Kim M; Jeong SU; Song C; Cho YM; Ro JY; Ahn H
    BMC Urol; 2018 Feb; 18(1):7. PubMed ID: 29394928
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation between upgrading of prostate biopsy and biochemical failure and unfavorable pathology after radical prostatectomy.
    Ozden C; Oztekin CV; Ugurlu O; Gokkaya S; Yaris M; Memis A
    Urol Int; 2009; 83(2):146-50. PubMed ID: 19752607
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
    Araki D; Wood BL; Othus M; Radich JP; Halpern AB; Zhou Y; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
    J Clin Oncol; 2016 Feb; 34(4):329-36. PubMed ID: 26668349
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
    BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of >/=8.
    Manoharan M; Bird VG; Kim SS; Civantos F; Soloway MS
    BJU Int; 2003 Oct; 92(6):539-44. PubMed ID: 14511029
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
    Iremashvili V; Pelaez L; Manoharan M; Jorda M; Rosenberg DL; Soloway MS
    Eur Urol; 2012 Sep; 62(3):462-8. PubMed ID: 22445138
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men.
    Jeldres C; Suardi N; Walz J; Hutterer GC; Ahyai S; Lattouf JB; Haese A; Graefen M; Erbersdobler A; Heinzer H; Huland H; Karakiewicz PI
    Eur Urol; 2008 Dec; 54(6):1306-13. PubMed ID: 18083294
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the Walz Nomogram and Presence of Secondary Circulating Prostate Cells for Predicting Early Biochemical Failure after Radical Prostatectomy for Prostate Cancer in Chilean Men.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
    Asian Pac J Cancer Prev; 2015; 16(16):7123-7. PubMed ID: 26514500
    [TBL] [Abstract][Full Text] [Related]  

  • 53. External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer.
    Roumiguié M; Beauval JB; Filleron T; Benoit T; Rischmann P; de la Taille A; Salomon L; Soulié M; Malavaud B; Ploussard G
    BJU Int; 2014 Dec; 114(6b):E113-E119. PubMed ID: 24684584
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer.
    Mitchell CR; Boorjian SA; Umbreit EC; Rangel LJ; Carlson RE; Karnes RJ
    BJU Int; 2012 Dec; 110(11):1709-13. PubMed ID: 22934913
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A new preoperative nomogram to predict minimal prostate cancer: accuracy and error rates compared to other tools to select patients for active surveillance.
    O'Brien BA; Cohen RJ; Ryan A; Sengupta S; Mills J
    J Urol; 2011 Nov; 186(5):1811-7. PubMed ID: 21944097
    [TBL] [Abstract][Full Text] [Related]  

  • 56. What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series.
    Gandaglia G; Ploussard G; Isbarn H; Suardi N; De Visschere PJ; Futterer JJ; Ghadjar P; Massard C; Ost P; Sooriakumaran P; Surcel CI; van der Bergh RC; Montorsi F; Ficarra V; Giannarini G; Briganti A;
    Urol Oncol; 2015 Apr; 33(4):164.e1-9. PubMed ID: 25620154
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Radical prostatectomy in high-risk prostate cancer: incidence of specimen-confined disease (pT2-pT3a N0R0) and outcomes.
    Mearini L; Nunzi E; Bini V; Lepri L; Bruno R; Porena M
    Urologia; 2014; 81(2):125-32. PubMed ID: 24474543
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DTCs in breast cancer: clinical research and practice.
    Janni W; Rack B; Kasprowicz N; Scholz C; Hepp P
    Recent Results Cancer Res; 2012; 195():173-8. PubMed ID: 22527504
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential.
    Nunez Bragayrac LA; Murekeyisoni C; Vacchio MJ; Attwood K; Mehedint DC; Mohler JL; Azabdaftari G; Xu B; Kauffman EC
    Prostate; 2017 Jul; 77(10):1076-1081. PubMed ID: 28547760
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.